Given that ECDHCC‐1 is a cancer cell line originating from vascular endothelium with potent angiogenic capabilities, in vitro tube formation assays demonstrated that inhibiting APLN expression significantly reduced the angiogenic capacity of ECDHCC‐1 in vitro (Figure 10E). This evidence concerns the gene APLN and cancer.